Core Insights - Akari Therapeutics, Plc is an oncology biotechnology company focused on developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, and has announced its abstract acceptance for presentation at the American Association for Cancer Research Annual Meeting 2026 [1][2] Group 1: Presentation Details - The poster presentation will focus on the rationale for developing a differentiated Trop2 ADC targeting solid tumors in the bladder, lung, and breast [2] - The presentation is scheduled for April 20, 2026, from 2:00 PM to 5:00 PM PT, under the session category of Experimental and Molecular Therapeutics [2] - The poster will be available for review on the company's website after the presentation [2] Group 2: Company Overview - Akari Therapeutics is developing next-generation ADCs, with its lead candidate AKTX-101 targeting the Trop2 receptor on cancer cells using a proprietary linker to deliver the PH1 payload directly into tumors [4] - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing within cancer cells, showing significant activity in preclinical studies and potential synergy with checkpoint inhibitors [4] - The company is also developing AKTX-102, targeting CEACAM5, which is expressed across multiple solid tumors, leveraging the same innovative PH1 payload [4]

Core Viewpoint - Akari Therapeutics is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares to comply with Nasdaq's minimum bid price requirement, effective March 31, 2026 [1][2]. Group 1: ADS Ratio Change - The new ratio will be one ADS representing eighty thousand (80,000) ordinary shares, changing from the previous ratio of one ADS representing two thousand (2,000) ordinary shares [1][2]. - Each ADS holder will need to exchange every forty ADSs for one new ADS [2]. - Deutsche Bank will facilitate the exchange of current ADSs for new ADSs, and there will be no change to Akari's underlying ordinary shares [2]. Group 2: Fractional ADSs - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [3]. Group 3: Company Overview - Akari Therapeutics is focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, targeting RNA splicing [4]. - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has shown significant activity in preclinical studies, with potential synergy with checkpoint inhibitors [4]. - Akari is also developing AKTX-102, targeting CEACAM5, leveraging the proprietary PH1 payload for differentiated tumor cell killing and immune activation [4].

Core Insights - Akari Therapeutics has appointed Dr. Prafulla Gokhale to its Scientific Advisory Board, enhancing its expertise in oncology drug development as it advances its lead candidate AKTX-101 toward clinical trials [1][2][4] Company Overview - Akari Therapeutics is focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing, differentiating it from conventional ADCs that use tubulin inhibitors or DNA-damaging agents [7] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has shown significant activity in preclinical studies, indicating prolonged survival compared to traditional ADCs [7] - The company is also developing AKTX-102, which targets CEACAM5, a tumor antigen expressed across multiple solid tumors, leveraging the same PH1 payload for enhanced therapeutic effects [7] Dr. Prafulla Gokhale's Role - Dr. Gokhale brings over 20 years of experience in preclinical oncology drug discovery and development, having previously led pharmacology teams at major pharmaceutical companies [4] - His expertise in experimental therapeutics and translational oncology is expected to strengthen Akari's clinical strategies for AKTX-101, ensuring a data-driven approach as the company prepares for first-in-human studies [2][6] Mechanism of Action - The PH1 payload is designed to modulate spliceosomes, disrupting RNA splicing within cancer cells, which has been shown to induce cancer cell death while engaging both innate and adaptive immune responses [5][7] - Preclinical models indicate that AKTX-101 may work synergistically with checkpoint inhibitors, enhancing its therapeutic potential [7]

Core Viewpoint - Akari Therapeutics has appointed Dr. Olga Anczukow to its Scientific Advisory Board, enhancing its expertise in RNA biology and cancer research, which is crucial for the development of next-generation therapeutics [1][2][4] Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing antibody drug conjugates (ADCs) with a unique payload, PH1, that targets RNA splicing in cancer cells [9] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, minimizing off-target effects [9] - AKTX-101 has shown significant activity in preclinical studies, demonstrating prolonged survival compared to traditional ADCs and potential synergy with checkpoint inhibitors [9] Dr. Olga Anczukow's Background - Dr. Anczukow is a recognized leader in RNA biology and cancer research, currently serving as an Associate Professor at The Jackson Laboratory for Genomic Medicine and a Co-Program Leader at the NCI-designated Jackson Laboratory Cancer Center [4][6] - Her research focuses on alternative RNA splicing and its misregulation in cancer, contributing to tumor initiation, progression, and therapeutic resistance [4][6] - Dr. Anczukow's previous work includes significant contributions to understanding breast cancer genetics and the role of RNA splicing in cancer biology [5][6] Research and Development Focus - The company aims to leverage Dr. Anczukow's expertise to shape research strategy and evaluate emerging scientific opportunities, particularly in RNA-targeted treatments [2][4] - Akari's innovative ADC discovery platform allows for the generation and optimization of ADC candidates tailored to specific antigen targets [9] - The ongoing research at The Jackson Laboratory integrates various methodologies to investigate how cancer cells adapt their splicing programs to survive and evade therapy [6]

Core Insights - Akari Therapeutics is expanding its antibody drug conjugate (ADC) pipeline and intellectual property strategy, as discussed by CEO Abizer Gaslightwala in a recent virtual investor interview [2][4] - The company is advancing its lead ADC program, AKTX-101, towards Investigational New Drug (IND) and Clinical Trial Application (CTA) submissions, aiming for first-in-human studies by late 2026 or early 2027 [4][6] ADC Pipeline Expansion - Akari has introduced AKTX-102, its second ADC candidate targeting CEACAM5-expressing solid tumors, highlighting the scalability of its PH1-powered ADC platform [3][4] - The company’s differentiated approach to CEACAM5 involves a novel antibody construct combined with the PH1 spliceosome-modulating payload [4] Intellectual Property Strategy - The recent patent filing is a significant milestone that supports Akari's long-term value creation and potential partnering opportunities [3][4] - The growing patent estate is strategically important for the company as it seeks to enhance its market position and protect its innovations [4] Lead Program Details - AKTX-101 targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, minimizing off-target effects [6] - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, with potential synergy with checkpoint inhibitors [6]

Core Insights - Akari Therapeutics is expanding its antibody drug conjugate (ADC) pipeline and intellectual property strategy, as discussed by CEO Abizer Gaslightwala in a recent virtual investor interview [2][4] - The company is advancing its lead ADC program, AKTX-101, towards IND and CTA submissions, aiming for first-in-human studies by late 2026 or early 2027 [4][6] ADC Pipeline Expansion - Akari has introduced AKTX-102, its second ADC candidate targeting CEACAM5-expressing solid tumors, highlighting the scalability of its PH1-powered ADC platform [3][4] - The company’s differentiated approach to CEACAM5 involves a novel antibody construct combined with the PH1 spliceosome-modulating payload [4] Intellectual Property Strategy - The recent patent filing underscores the strategic importance of Akari's growing patent estate, which supports long-term value creation and potential partnering opportunities [4] - The company aims to leverage its innovative ADC discovery platform to generate and optimize ADC candidates for various antigen targets [6] Lead Program Details - AKTX-101 targets the Trop2 receptor on cancer cells, utilizing a proprietary linker to deliver the PH1 payload directly into tumors with minimal off-target effects [6] - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, with potential synergy with checkpoint inhibitors [6]

Core Viewpoint - Akari Therapeutics is advancing its next-generation antibody drug conjugates (ADCs) with a focus on its proprietary PH1 spliceosome-modulating payload, aiming to initiate first-in-human trials for its lead program, AKTX-101, by late 2026 or early 2027 [2][4]. Company Overview - Akari Therapeutics is an oncology biotechnology company specializing in ADCs that utilize a unique payload, PH1, which targets RNA splicing [4]. - The company has developed a platform that allows for the generation and optimization of ADC candidates tailored to specific antigen targets [4]. Lead Programs - The lead program, AKTX-101, targets the Trop2 receptor on cancer cells and is designed to deliver the PH1 payload directly to tumors with minimal off-target effects [2][4]. - AKTX-101 has shown significant activity in preclinical studies, leading to prolonged survival compared to traditional ADCs [4]. - The company is also advancing AKTX-102, another ADC program focused on gastrointestinal (GI) and lung cancers [2][4]. Upcoming Events - Akari Therapeutics will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026, where CEO Abizer Gaslightwala will present a corporate overview and updates on the company's programs [1][3].

Core Insights - Akari Therapeutics is expanding its pipeline with a new ADC candidate, AKTX-102, targeting CEACAM5, a significant solid tumor marker in oncology [1][3] - The company has filed a U.S. provisional patent application for AKTX-102, which utilizes a proprietary PH1 spliceosome payload to enhance therapeutic efficacy [1][5] Pipeline and Product Development - AKTX-102 is designed to address CEACAM5, which is expressed in 80-90% of gastrointestinal cancers and has been linked to aggressive cancer subtypes [2][4] - The ADC combines a novel antibody construct with the PH1 payload, aiming to improve tumor cell killing and activate immune responses [3][4] Intellectual Property and Innovation - The new patent filing enhances Akari's intellectual property portfolio, which includes previous filings focused on novel mechanisms and combination strategies [5][6] - Akari's patent estate is expected to support the development of multiple first- and best-in-class ADC candidates across various cancer targets [6] Market Opportunity and Challenges - CEACAM5 has been a challenging target in oncology due to its complex biology, but Akari's approach aims to overcome these hurdles [7][8] - The company’s strategy includes addressing CEACAM5's role as an immunosuppressive checkpoint, which has historically limited therapeutic success [8][9] Clinical Development and Future Plans - Akari is advancing its lead program, AKTX-101, towards IND/CTA submission and first-in-human trials, with a goal to initiate by late 2026 or early 2027 [10][13] - The company is also pursuing partnerships to leverage its unique PH1 payload and ADC approach [13]

Core Insights - Akari Therapeutics is progressing towards becoming a clinical-stage oncology company in 2026, with significant milestones achieved in 2025 [3][4] - The company is developing a novel payload, PH1, for its antibody-drug conjugates (ADCs), which has shown promising preclinical efficacy and safety [4][6] - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has demonstrated significant activity and prolonged survival in preclinical studies [6] Company Developments - In 2025, Akari established a strategic manufacturing partnership with WuXi Biologics to support clinical readiness [4] - The company plans to initiate its First-in-Human clinical trial for AKTX-101 by late 2026 or early 2027 [6] - Akari is also advancing another ADC candidate, AKTX-102, targeting a novel antigen relevant in gastrointestinal and lung cancers [6] Scientific Innovations - The PH1 payload is designed to disrupt RNA splicing within cancer cells, leading to cancer cell death while activating the immune system [6] - AKTX-101 has the potential for synergy with checkpoint inhibitors, showing prolonged survival both as a single agent and in combination therapies [6] - The PH1 payload has demonstrated activity against cancer cells with key oncogenic drivers such as KRAS, BRAF, and ARV7 [6]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing [3] - The company's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors with minimal off-target effects [3] - AKTX-101 has shown significant activity and prolonged survival in preclinical studies compared to traditional ADCs, and it has the potential to be synergistic with checkpoint inhibitors [3] Strategic Priorities - Akari Therapeutics aims to initiate IND enabling studies for AKTX-101, with a goal of starting its First-In-Human trial by late 2026 or early 2027 [3] - The company is also advancing AKTX-102, an ADC targeting a novel antigen relevant in gastrointestinal and lung cancers [3] Upcoming Presentation - Abizer Gaslightwala, President and CEO of Akari Therapeutics, will present at the 2026 Biotech Showcase on January 13, 2026, at 9:30 AM PST [1][2] - The presentation will cover an overview of Akari's ADC platform, strategic priorities, and key milestones for 2026 [1]